SCHEMBL5940

SCHEMBL5940

OB(O)c1ccc2[nH]ccc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 1/20 0.71
USP2 O75604 1/20 0.55
GAA P10253 1/20 0.55
ALOX15 P16050 1/20 0.55
RAD51 Q06609 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
AHR P35869 4/20 0.50
NR4A2 P43354 2/20 0.50
CYP2A6 P11509 2/20 0.50
F7 P08709 1/20 0.50
LTA4H P09960 1/20 0.50
F3 P13726 1/20 0.50
F2 P00734 1/20 0.47
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
IMPDH2 P12268 1/20 0.46
IMPDH1 P20839 1/20 0.46
NPC1 O15118 1/20 0.46
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29444118 1.00 ENPP2 (0.71) ENPP2USP2GAAALOX15RAD51
SCHEMBL28032697 0.84 ENPP2 (0.53) ENPP2USP2GAAALOX15RAD51
SCHEMBL29419532 0.83 ENPP2 (1.00) ENPP2USP2GAAALOX15RAD51
SCHEMBL6091 0.83 ENPP2 (1.00) ENPP2USP2GAAALOX15RAD51
SCHEMBL1795397 0.80 F2 (0.49) ENPP2USP2GAAALOX15RAD51
SCHEMBL9946107 0.79 AHR (0.50) ENPP2USP2GAAALOX15RAD51
SCHEMBL28853917 0.77 ENPP2 (0.45) ENPP2USP2GAAALOX15RAD51
SCHEMBL14983547 0.75 TUBB4A (0.47) ENPP2USP2GAAALOX15RAD51
SCHEMBL13086174 0.73 ENPP2 (0.53) ENPP2CA1CA2
SCHEMBL205203 0.71 CA2 (0.80) ENPP2CA1CA2CA4CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1426 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118854271-A Cyanide-free gold plating solution and preparation method and application thereof 生益电子股份有限公司 2024-10-29 CN claimed
CN-118598859-A Nitrogenous heterocyclic indole xanthine oxidase inhibitor and preparation method and application thereof 武汉工程大学 2024-09-06 CN claimed
CN-116283946-B 5- (N-substituted indole-5-yl) isoxazole-3-formic acid derivative and synthetic method and application thereof 武汉工程大学 2024-05-07 CN claimed
CN-116283946-A 5- (N-substituted indole-5-yl) isoxazole-3-formic acid derivative and synthetic method and application thereof 武汉工程大学 2023-06-23 CN claimed
US-11495769-B2 Inorganic light emitting diode and inorganic light emitting device including the same LG DISPLAY CO., LTD. (KR) 2022-11-08 US claimed
CN-114686205-A Modification method of quantum dot material, modified quantum dot material and light-emitting device TCL科技集团股份有限公司 2022-07-01 CN claimed
US-20210167321-A1 INORGANIC LIGHT EMITTING DIODE AND INORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME LG DISPLAY CO., LTD. (KR) 2021-06-03 US claimed
CN-111040758-A Preparation method and application of polybenzazole boric acid modified carbon quantum dot composite material 中国林科院林产化工研究所南京科技开发总公司 2020-04-21 CN claimed
WO-2012109735-A1 METHODS OF PREPARING CYCLIC AMINO ACID MOLECULES USING ARYLBORONIC OR ARYLBORINIC ACID CATALYSTS THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2012-08-23 WO claimed
US-7037905-B2 Pharmaceutical use of boronic acids and esters thereof NOVO NORDISK A/S (DK) 2006-05-02 US claimed
US-20040053889-A1 Pharmaceutical use of boronic acids and esters thereof NOVO NORDISK A/S (DK) 2004-03-18 US claimed
EP-4212523-B1 PYRAZOLE AMIDE COMPOUNDS AS IRAK INHIBITORS RIGEL PHARMACEUTICALS INC (US) 2026-05-06 EP disclosed
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) 2026-04-02 US disclosed
US-20260070880-A1 DYNAMIN ACTIVATORS WALDEN BIOSCIENCES, INC. (US) 2026-03-12 US disclosed
US-12570632-B2 Indole derivatives and uses thereof for treating a cancer UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2026-03-10 US disclosed
US-6242493-B1 PROSTAGLANDIN INHIBITORS; ANALGESICS, ANTIPYRETICS, ANTIINFLAMMATORY AGENTS MERCK FROSST CANADA & CO. (CA) 2001-06-05 US disclosed
EP-1071648-A2 CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT Merck Frosst Canada & Co. (CA) 2001-01-31 EP disclosed
WO-2001005784-A1 NITROGEN CONTAINING HETEROBICYCLES AS FACTOR Xa INHIBITORS BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-01-25 WO disclosed
WO-2000035909-A1 4-ARYLOXINDOLES AS INHIBITORS OF JNK PROTEIN KINASES F. HOFFMANN-LA ROCHE AG (CH) 2000-06-22 WO disclosed
WO-1999047497-A2 CARBOXYLIC ACIDS AND ACYLSULFONAMIDES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK FROSST CANADA & CO. (CA) 1999-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570632-B2 Indole derivatives and uses thereof for treating a cancer CKS2, CSNK2A3, CSNK1A1L ENPP2 3649/4885USP2 2115/4885GAA 4112/4885
US-20040053889-A1 Pharmaceutical use of boronic acids and esters thereof LIPE, CEL, LIPA ENPP2 998/4885USP2 776/4885GAA 11/4885
US-20260070880-A1 DYNAMIN ACTIVATORS DNM1, DNM1L, DNM2 ENPP2 1807/4885USP2 4344/4885GAA 1109/4885
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof STS, NR5A1, CYP21A2 ENPP2 3779/4885USP2 1571/4885GAA 3943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.